Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS002 in Homozygous Familial Hypercholesterolemia
NCT04515927Phase 2Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Aug 2020
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ongericimab in homozygous familial hypercholesterolemia (HoFH), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Aug 2020; status: completed.
02
Drugs
ongericimab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT04515927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04515927.